Hemophilia A & B: Modern Treatment & Gene Therapy Access

Hemophilia is an inherited bleeding disorder caused by deficiency of clotting factor VIII (Hemophilia A) or factor IX (Hemophilia B) -- proteins essential for normal blood clotting. Both genes are on the X chromosome, following X-linked recessive inheritance: males with one affected X chromosome develop the disease, while females with one affected X are typically carriers. Approximately 30% of new cases arise from de novo mutations with no family history.

Hemophilia A (factor VIII deficiency) accounts for approximately 80% of cases; Hemophilia B (factor IX deficiency, or Christmas Disease) accounts for approximately 20%. Both cause identical clinical bleeding symptoms but require different replacement products. Emicizumab (Hemlibra) and valoctocogene gene therapy are specific to Hemophilia A; etranacogene dezaparvovec gene therapy is for Hemophilia B. Fitusiran works for both types.

Inhibitors are antibodies the immune system produces against infused factor replacement products, neutralizing their therapeutic effect. They develop in approximately 25-30% of patients with severe Hemophilia A and about 3-5% with severe Hemophilia B. Inhibitors make standard factor replacement ineffective and significantly worsen disease management. Treatment options include emicizumab prophylaxis (Hemophilia A), bypassing agents for acute bleeds, and immune tolerance induction (ITI) -- a prolonged high-dose FVIII regimen that can eradicate inhibitors in 60-80% of patients.

Emicizumab (Hemlibra) is a bispecific antibody that bridges activated factor IXa and factor X -- mimicking the bridging function that factor VIII normally performs. It is administered by subcutaneous self-injection weekly, biweekly, or monthly. Because it does not resemble FVIII structurally, it is not neutralized by anti-FVIII inhibitors, making it equally effective in patients with and without inhibitors. It is approved for Hemophilia A prophylaxis and has dramatically reduced bleeding rates, eliminated regular IV infusions for many patients, and significantly improved quality of life.

Yes -- gene therapies for both Hemophilia A and B have received regulatory approval. Valoctocogene roxaparvovec (Roctavian) is approved for adults with severe Hemophilia A without pre-existing anti-AAV5 antibodies. Etranacogene dezaparvovec (Hemgenix) is approved for adults with moderate-to-severe Hemophilia B. Both are one-time IV infusions delivering functional factor genes, achieving sustained factor expression with significant reduction or elimination of bleeds. Long-term durability and response variability are areas of ongoing study and patient counseling.

Prophylaxis means scheduled regular infusions of factor concentrate or subcutaneous emicizumab to maintain protective factor levels before bleeds can occur. It is the standard of care for severe hemophilia because it dramatically reduces bleed frequency, preserves joint function, and prevents hemophilic arthropathy -- the leading cause of disability in untreated disease. Early initiation in childhood before the first joint bleed is associated with significantly better long-term joint outcomes.

Medications that impair platelet function or anticoagulate the blood should be avoided unless specifically directed by the HTC team: aspirin, NSAIDs (ibuprofen, naproxen), and anticoagulants (warfarin, heparin, DOACs). Intramuscular injections should be avoided. High-impact contact sports require careful risk discussion with the HTC team. Low-impact activities like swimming, cycling, and walking are generally safe and recommended.

Hemophilia predominantly affects males due to X-linked inheritance. However, female carriers can have significantly reduced factor levels and may experience heavy menstrual bleeding, postpartum hemorrhage, or prolonged bleeding after procedures. Females develop hemophilia if they inherit two affected X chromosomes or if one X chromosome is preferentially inactivated. Female carriers should have their factor levels measured and receive pre-procedural and obstetric planning from a specialist hemophilia team.

Yes. CancerFax connects patients with hemophilia to specialist hemophilia treatment centers experienced in comprehensive management -- including extended half-life factor products, emicizumab for Hemophilia A with or without inhibitors, immune tolerance induction for inhibitor management, gene therapy programs (valoctocogene for Hemophilia A, etranacogene for Hemophilia B), fitusiran, and clinical trials for emerging non-factor therapies. CancerFax facilitates medical report review, specialist second opinions, and coordination with leading hemophilia centers in India and internationally.